文献速递临床试验与 GCP流行病学与生物统计

GOAL试验研究方案:针对体弱老年慢性肾脏病患者的综合老年评估以提高患者自定目标的达成率——一项整群随机对照试验

Study protocol for The GOAL Trial: comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient-identified goals-a cluster randomised controlled trial.
PubMed 文献 · Trials · 2023-05-30

GOAL试验是一项由消费者、临床医生和研究者共同制定的实用性、多中心、开放标签、优效性整群随机对照试验,采用两组设计,比较综合老年评估(CGA)与标准护理,共16个整群按1:1分配。纳入≥65岁(原住民或托雷斯海峡岛民≥55岁)、CKD 3-5/5D期且衰弱指数>0.25的患者。主要结局为3个月时通过标准化目标达成量表(GAS)评估的自定目标达成情况。

要点

  • GOAL试验比较CGA与标准护理对体弱老年CKD患者自定目标达成的影响。
  • 主要结局为3个月时标准化GAS评估的目标达成情况。
  • 试验有90%把握度检测GAS均值差异10个单位。

核心结论

  • 若CGA对体弱老年CKD患者具有临床和成本效果,该干预框架可嵌入常规临床实践。

研究设计与样本

  • 实用性、多中心、开放标签、优效性整群随机对照试验,由消费者、临床医生和研究者共同制定。
  • 两组设计,CGA与标准护理比较,共16个整群按1:1分配。
  • 纳入≥65岁(原住民或托雷斯海峡岛民≥55岁)、CKD 3-5/5D期、衰弱指数>0.25的患者。
  • 干预组由老年科医生进行CGA以识别医疗、社会和功能需求,优化药物处方,必要时安排多学科转诊;标准护理组接受常规护理。
  • 主要结局为3个月时通过标准化目标达成量表(GAS)评估的自定目标达成情况。

主要发现

  • 试验有90%把握度检测GAS均值差异10个单位。
  • 次要结局包括6个月和12个月的GAS、生活质量(EQ-5D-5L)、衰弱(衰弱指数-简表)、转至住宿式老年护理机构、成本效果和安全性(特定原因住院、死亡)。
  • 将平行进行过程评估,包括干预是否按预期实施、实施中的问题或局部障碍以及参与者对干预的看法。

临床怎么用

  • 若CGA被发现有临床和成本效果,干预框架可嵌入常规临床实践。
  • 试验结果的实施将通过会议和论坛展示以及与临床医生和消费者的专门研讨会支持,以促进肾脏病学和老年医学学科的快速采纳。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An increasing number of older people are living with chronic kidney disease (CKD). Many have complex healthcare needs and are at risk of deteriorating health and functional status, which can adversely affect their quality of life. Comprehensive geriatric assessment (CGA) is an effective intervention to improve survival and independence of older people, but its clinical utility and cost-effectiveness in frail older people living with CKD is unknown. METHODS: The GOAL Trial is a pragmatic, multi-centre, open-label, superiority, cluster randomised controlled trial developed by consumers, clinicians, and researchers. It has a two-arm design, CGA compared with standard care, with 1:1 allocation of a total of 16 clusters. Within each cluster, study participants ≥ 65 years of age (or ≥ 55 years if Aboriginal or Torres Strait Islander (First Nations Australians)) with CKD stage 3-5/5D who are frail, measured by a Frailty Index (FI) of > 0.25, are recruited. Participants in intervention clusters receive a CGA by a geriatrician to identify medical, social, and functional needs, optimise medication prescribing, and arrange multidisciplinary referral if required. Those in standard care clusters receive usual care. The primary outcome is attainment of self-identified goals assessed by standardised Goal Attainment Scaling (GAS) at 3 months. Secondary outcomes include GAS at 6 and 12 months, quality of life (EQ-5D-5L), frailty (Frailty Index - Short Form), transfer to residential aged care facilities, cost-effectiveness, and safety (cause-specific hospitalisations, mortality). A process evaluation will be conducted in parallel with the trial including whether the intervention was delivered as intended, any issue or local barriers to intervention delivery, and perceptions of the intervention by participants. The trial has 90% power to detect a clinically meaningful mean difference in GAS of 10 units. DISCUSSION: This trial addresses patient-prioritised outcomes. It will be conducted, disseminated and implemented by clinicians and researchers in partnership with consumers. If CGA is found to have clinical and cost-effectiveness for frail older people with CKD, the intervention framework could be embedded into routine clinical practice. The implementation of the trial's findings will be supported by presentations at conferences and forums with clinicians and consumers at specifically convened workshops, to enable rapid adoption into practice and policy for both nephrology and geriatric disciplines. It has potential to materially advance patient-centred care and improve clinical and patient-reported outcomes (including quality of life) for frail older people living with CKD. TRIAL REGISTRATION: ClinicalTrials.gov NCT04538157. Registered on 3 September 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Logan B, Viecelli AK, Johnson DW, et al. Study protocol for The GOAL Trial: comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient-identified goals-a cluster randomised controlled trial. Trials. 2023. PMID: 37254217. doi:10.1186/s13063-023-07363-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。